MM4TB
More Medicines for Tuberculosis
| Coordinatore |
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
| Nazionalità Coordinatore | Non specificata |
| Totale costo | 16˙695˙126 € |
| EC contributo | 11˙873˙052 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-02-01 - 2016-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
CH (LAUSANNE) | coordinator | 2˙301˙083.20 |
| 2 |
AstraZeneca India Pvt Ltd.
Organization address
address: "'AVISHKAR', BELLARY ROAD" contact info |
IN (BANGALORE) | participant | 742˙191.50 |
| 3 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 700˙000.00 |
| 4 |
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
Organization address
address: Pierre Brossolette 1 contact info |
FR (Chilly Mazarin) | participant | 600˙000.00 |
| 5 |
UNIVERSITA DEGLI STUDI DI PAVIA
Organization address
address: STRADA NUOVA 65 contact info |
IT (PAVIA) | participant | 600˙000.00 |
| 6 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 562˙461.60 |
| 7 |
"Institution of the Russian Academy of Sciences, A.N. Bach Institute of Biochemistry of RAS"
Organization address
address: Leninsky Prospect 33 contact info |
RU (MOSCOW) | participant | 500˙000.00 |
| 8 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | participant | 500˙000.00 |
| 9 |
TYDOCK PHARMA S.r.l
Organization address
address: Strada Gherbella 294/b contact info |
IT (Modena) | participant | 499˙800.00 |
| 10 |
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH
Organization address
address: Raemistrasse 101 contact info |
CH (ZUERICH) | participant | 450˙000.00 |
| 11 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 450˙000.00 |
| 12 |
UNIVERZITA KOMENSKEHO V BRATISLAVE
Organization address
address: SAFARIKOVO NAM 6 contact info |
SK (Bratislava 1) | participant | 425˙000.00 |
| 13 |
JOHN INNES CENTRE
Organization address
address: "Norwich Research Park, Colney" contact info |
UK (NORWICH) | participant | 400˙000.00 |
| 14 |
VICHEM CHEMIE KUTATO KFT
Organization address
address: HERMANN OTTO UTCA 15 contact info |
HU (BUDAPEST) | participant | 400˙000.00 |
| 15 |
UNIVERSITA DEGLI STUDI DI PADOVA
Organization address
address: VIA 8 FEBBRAIO 2 contact info |
IT (PADOVA) | participant | 375˙000.00 |
| 16 |
UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO
Organization address
address: DUOMO 6 contact info |
IT (VERCELLI) | participant | 350˙000.00 |
| 17 |
QUEEN MARY UNIVERSITY OF LONDON
Organization address
address: 327 MILE END ROAD contact info |
UK (LONDON) | participant | 300˙000.00 |
| 18 |
COLLABORATIVE DRUG DISCOVERY INC CORPORATION
Organization address
address: BAYSHORE HIGHWAY 1633 SUITE 342 contact info |
US (BURLINGAME CA) | participant | 255˙000.00 |
| 19 |
CELLWORKS RESEARCH INDIA PRIVATE LIMITED
Organization address
address: "3rd Floor, West Wing, Neil Rao Tower, EPIP Whitefield 118, Road 3" contact info |
IN (BANGALORE) | participant | 250˙000.00 |
| 20 |
UNIVERSIDAD DE ZARAGOZA
Organization address
address: CALLE PEDRO CERBUNA 12 contact info |
ES (Zaragoza) | participant | 250˙000.00 |
| 21 |
UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA
Organization address
address: BARRIO SARRIENA S N contact info |
ES (LEIOA) | participant | 250˙000.00 |
| 22 |
UNIVERSITY OF CAPE TOWN
Organization address
address: PRIVATE BAG X3 contact info |
ZA (RONDEBOSCH) | participant | 250˙000.00 |
| 23 |
INDIAN INSTITUTE OF SCIENCE
Organization address
address: CROSS MALLESHWARAM 18 contact info |
IN (BANGALORE) | participant | 162˙000.00 |
| 24 |
SCIPROM SARL
Organization address
address: RUE DU CENTRE 70 contact info |
CH (Saint-Sulpice) | participant | 150˙515.62 |
| 25 |
Alere Technologies GmbH
Organization address
address: Loebstedter Str. 103-105 contact info |
DE (Jena) | participant | 150˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be implemented by a multidisciplinary team that combines some of Europe's leading academic TB researchers with two major pharmaceutical companies and four SMEs, all strongly committed to the discovery of anti-infective agents. MM4TB will use a tripartite screening strategy to discover new hits in libraries of natural products and synthetic compounds, while concentrating on both classical and innovative targets that have been pharmacologically validated. Whole cell screens will be conducted against Mycobacterium tuberculosis using in vitro and ex vivo models for active growth, latency and intracellular infection. Hits that are positive in two or more of these models will then be used for target identification using functional genomics technologies including whole genome sequencing and genetic complementation of resistant mutants, yeast three hybrid, click chemistry and proteomics. Targets thus selected will enter assay development, structure determination, fragment-based and rational drug design programs; functionally related targets will be found using metabolic pathway reconstruction. Innovative techniques, based on microfluidics and array platforms, will be used for hit ranking, determining rates of cidality and confirming mechanism of action. Medicinal chemistry will convert leads to molecules with drug-like properties for evaluation of efficacy in different animal models and late preclinical testing.'
Introduzione (Teaser)
An international scientific alliance is working to deliver novel drugs for treatment of the poverty-related disease tuberculosis (TB).
Descrizione progetto (Article)
TB remains one of the major health threats worldwide and in past years it has resurged in Europe. It is caused by Mycobacterium tuberculosis (MTb) and its treatment entails prolonged administration of antibiotics. However, the emergence of drug-resistant species is a frequent phenomenon, which needs to be addressed immediately.
The EU-funded 'More medicines for tuberculosis' (http://www.mm4tb.org/ (MM4TB)) project has set out to discover and validate new drug targets and pharmaceuticals for the treatment of TB. Its predecessor project NM4TB discovered the benzothiazinone (BTZ) drug, which is currently under pre-clinical development.
In the first part of the project, researchers screened libraries of synthetic compounds and natural products to identify molecules that could eliminate MTb. The inhibitory potency of the selected compounds has been tested on the active, latent and intracellular phases of bacterial growth. Real-time single-cell microscopy was employed to assess the toxicity of the promising candidate compounds.
To identify new drug targets, scientists used drugs with known anti-TB activity and isolated emerging resistant clones. Genomic sequencing of resistant bacteria led to identification of the affected genes. After validation, selection of targets was based on certain criteria, including specificity and accessibility to the drug.
Furthermore, the consortium is designing drugs against key components of MTb survival, such as enzymes implicated in cell wall biosynthesis or metabolism. These targets are being extensively characterised in terms of their biochemical properties and their 3D structure by crystallography. Using this information, researchers are resynthesising candidate compounds to optimise their properties.
The activities of the MM4TB project towards drug discovery will be continued in collaboration with pharmaceutical companies to meet their goal of delivering effective anti-TB compounds. Given the global dimensions of the disease, new treatments will alleviate the suffering of millions of individuals around the world.